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Effectiveness of antibiotics given before admission in reducing
mortality from meningococcal disease: systematic review
Susan J M Hahné, André Charlett, Bernadette Purcell, Susanne Samuelsson, Ivonne Camaroni, Ingrid Ehrhard,
Sigrid Heuberger, Maria Santamaria, James M Stuart
Abstract
Objective To review the evidence for effectiveness of treatment
with antibiotics before admission in reducing case fatality from
meningococcal disease.
Design Systematic review.
Data sources Cochrane register of trials and systematic reviews,
database of abstracts of reviews of effectiveness, health
technology assessment, and national research register in
England and Wales, Medline, Embase, and CAB Health.
Included studies Studies describing vital outcome of at least 10
cases of meningococcal disease classified by whether or not
antibiotics were given before admission to hospital.
Results 14 observational studies met the review criteria. Oral
antibiotic treatment given before admission was associated with
reduced mortality among cases (combined risk ratio 0.17, 95%
confidence interval 0.07 to 0.44). In seven studies in which all
included patients were seen in primary care, the association
between parenteral antibiotics before admission and outcome
was inconsistent (2 for heterogeneity 11.02, P = 0.09). After
adjustment for the proportion given parenteral antibiotics
before admission, there was no residual heterogeneity. A higher
proportion of patients given parenteral antibiotics before
admission was associated with reduced mortality after such
treatment and vice versa (P = 0.04).
Conclusion Confounding by severity is the most likely
explanation both for the beneficial effect of oral antibiotics and
the harmful effect observed in some studies of parenteral
antibiotics. We cannot conclude whether or not antibiotics given
before admission have an effect on case fatality. The data are
consistent with benefit when a substantial proportion of cases
are treated.
Introduction
Invasive meningococcal disease is one of the most destructive
acute infections in humans and remains an important cause of
death in children in developed countries. Reducing such mortal-
ity depends on successful prevention and treatment. In most
European countries, prevention of meningococcal disease is
based on chemoprophylaxis and immunisation in contacts of
patients with meningococcal disease. The United Kingdom, Ire-
land, Spain, Luxembourg, Belgium, and the Netherlands have
started childhood immunisation programmes with a conjugate
vaccine against Neisseria meningitidis serogroup C meningococ-
cal disease. Attempts to reduce case fatality further remain nec-
essary as in Europe most invasive meningococcal disease is
caused by group B organisms,1 for which a vaccine providing
broad protection is not yet available.2
Mortality in patients with invasive meningococcal disease
depends on variables including the age of the patient, the clinical
manifestation (septicaemia/meningitis), characteristics of the
organism (clonal complex), and case management.3 Of these,
only case management can be influenced by therapeutic
intervention. Before serum therapy and effective antibiotic
therapy were available, about 70% of patients with invasive
meningococcal disease died.4 After the introduction of treatment
with antibiotics such as benzyl penicillin and cephalosporins,
case fatality fell to around 10%. A tertiary care referral centre
recently reported further reductions in case fatality that they
attributed to improved clinical management.5
As meningococcal disease often progresses rapidly, it is not
surprising that delays in starting antibiotic treatment in hospital
have an adverse effect on outcome.6 Whether giving antibiotics
in primary care (that is, before admission) improves outcome of
meningococcal disease, however, remains uncertain because
studies of effectiveness show inconsistent results.7 8 This absence
of consensus is reflected in differing policies across Europe. Sev-
eral countries, including the UK,9 Ireland, and France, advise all
doctors in primary care to consider giving parenteral antibiotics
to all patients with suspected meningococcal disease before
transfer to hospital. Many other countries do not give specific
advice regarding such treatment.
A 1999 survey among members of the European Monitoring
Group on Meningococci (EMGM) identified antibiotics before
admission as one of the interventions for which public health
policy differed most within Europe (J Stuart, personal communi-
cation). Chemoprophylaxis to prevent secondary cases of
meningococcal disease is another, though a systematic review
has shown it to be effective.10 We reviewed the evidence for effec-
tiveness of antibiotic treatment before admission on survival of
patients with meningococcal disease to inform treatment
policies in countries where these patients are likely to be seen
initially in primary care.
Methods
We searched the Cochrane register of trials and systematic
reviews, the database of abstracts of reviews of effectiveness, the
health technology assessment and the national research register
in England and Wales, Medline (1 January 1966 to 31 January
2005), Embase (1 January 1983 to 31 January 2005), and CAB
Health (1 January 1973 to 31 January 2005). The textword terms
and MESH headings used were: “meningococcal infections”,
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“Neisseria meningitis”, “chemoprevention”, “prophylaxis”, “che-
moprophylaxis”, “antibiotics”, “drug therapy”, “primary health
care”, “patient care management”, “community health services”,
“communicable disease control”, “disease outbreaks”, “disease
transmission”, “cluster”, “outbreak”, “carrier state”, “cases”,
“household”. In addition, we checked bibliographies of existing
reviews for potentially relevant papers. We contacted the
Cochrane Acute Respiratory Infections group, WHO, the Euro-
pean Monitoring Group on Meningococci, the Communicable
Disease Surveillance Centre in the UK, and the Centers for Dis-
ease Control and Prevention in the United States for data that
might be eligible for inclusion. We did not restrict on language.
We examined all titles, and abstracts when available, and
retrieved full text of papers if we expected them to contain
primary data on antibiotic treatment of meningococcal disease
before admission and vital outcome. Studies met inclusion crite-
ria if they contained information on vital outcome of meningo-
coccal disease and whether patients were treated with parenteral
(intravenous or intramuscular) or oral antibiotics before
admission and if they included at least 10 patients. Two reviewers
independently assessed whether these papers met criteria for
inclusion in the review. If we identified two or more papers
including the same data, we included only the one with the most
data. We extracted data on numbers of deaths stratified by treat-
ment before admission to calculate unadjusted risk ratios. In
studies presenting data on both oral and parenteral antibiotic
treatment, patients treated with oral antibiotics were classified as
“untreated” when we analysed effect of parenteral antibiotics.
Statistical analysis
We combined results of individual studies using the metan com-
mand in Stata11 assuming random effects. Pooled estimates of the
risk ratio for death were obtained with the method of DerSimo-
nian and Laird. In those studies in which there were no deaths in
patients treated with antibiotics, we added 0.5 to each of the four
cells in the 2×2 table before analysis. We tested heterogeneity
using the appropriately weighted sum of the estimated log risk
ratios from individual studies minus the Mantel-Haenszel pooled
estimate. Heterogeneity was quantified by 2 and I2, which can be
interpreted as the percentage of the total variation between stud-
ies that is attributable to heterogeneity rather than to chance.12 In
the resulting forest plots, the size of the circles presenting point
estimates of the risk ratio for death is proportional to the weight
of the study in the meta-analysis. We investigated heterogeneity
between studies by stratifying by severity and by applying meta-
regression (the metareg command in Stata). We carried out
meta-regression by using two random effect regression models,
separately including two study level covariates: the proportion of
cases treated with parenteral antibiotics before admission and
the proportion of cases classified as severe. The natural
logarithm of the risk ratio and its standard error as estimated in
the random effects meta-analysis have been used as the depend-
ent variable and the within study standard error, respectively. We
estimated the variance between studies with an iterative
maximum likelihood approach.13
Results
The search yielded a total of 2620 references. After we examined
all titles and available abstracts, we retained 66 papers. We iden-
tified five more potentially useful papers by searching reference
lists of included papers and one more through contact with
experts. Both reviewers agreed that 14 papers met the criteria for
inclusion in the study (fig 1).8 14–26 All 14 papers were
observational cohort studies; no case-control study or ran-
domised controlled trial met the inclusion criteria. The overall
case fatality ratio was 6.0%, ranging from 3.3%14 to 14.6%.26
Twelve studies included both microbiologically confirmed and
clinically diagnosed cases of meningococcal disease.8 14–16 18–23 25 26
Two studies included only microbiologically confirmed cases.17 24
Some studies included data from earlier publications by the
same research group.18 19 We did not include these earlier
studies7 27 28 in our analysis.
Oral antibiotics given before admission
In all five studies that included data on oral antibiotics given
before admission this treatment was associated with reduced
mortality (combined risk ratio 0.17, 95% confidence interval 0.07
to 0.44; table 1 and fig 2). In one study this effect was significant
(P < 0.05).18 The test for heterogeneity resulted in a 2 of 2.29
(P = 0.68), I2 = 0% (95% uncertainty interval 0% to 79%).
Parenteral antibiotics given before admission
Twelve papers contained information on parenteral antibiotics
given before admission and outcome. Eight papers showed a
beneficial effect and four an adverse effect (table 2). One benefi-
cial effect was significant.14 Seven studies presented data on
Table 1 Cases of meningococcal disease and outcome stratified by oral antibiotic treatment before admission, excluding patients treated with parenteral
antibiotics before admission
Study Primary care*
No of deaths/No
treated
No of deaths/No not
treated Total (% treated) Case fatality (%) Risk ratio for death† (95% CI)
Norgard19 Yes 0/27 26/375 402 (7) 6.5 0.25 (0.02 to 4.05)
Morant17 No 1/35 7/104 139 (25) 5.8 0.42 (0.05 to 3.33)
Barquet18 No 2/241 38/361 602 (40) 6.6 0.08 (0.02 to 0.32)
Strang26 Yes 0/5 6/23 28 (18) 21.4 0.31 (0.02 to 4.74)
Garcia24 No 0/16 7/58 74 (22) 9.5 0.23 (0.01 to 3.85)
Total — 3/324 84/921 1245 (26) 7.0 0.17 (0.07 to 0.44)
*Study restricted to patients seen in primary care.
†In studies in which there were no deaths in patients treated with antibiotics, we added 0.5 to each of the four cells in the 2×2 table before the analysis.
Citations identified (n=2620)
Articles included (n=14)
Excluded (n=2554)
Full text articles reviewed for meeting inclusion criteria (n=72)
Excluded (n=58)
Full text articles selected for potential inclusion (n=66)
Additional studies identified (n=6)
Fig 1 Eligibility of studies for inclusion in systematic review
Research
page 2 of 5 BMJ Online First bmj.com
 on 26 October 2006 bmj.comDownloaded from 
patients seen in primary care (fig 3). The 2 for heterogeneity was
11.02 (P = 0.09), I2 = 46% (95% uncertainty interval 0% to 77%).
The proportion of cases treated differed among these studies,
ranging from 15%23 to 59% (P < 0.001).25 The results were similar
when we included all 12 studies in the analysis (2 for heteroge-
neity 16.94, P = 0.11).
Parenteral antibiotics before admission in patients with
“severe” disease
Five papers included data stratified by severity of disease. The
proportion of all cases classified as severe differed between stud-
ies, ranging from 11%19 to 76%26 (P < 0.001). Severe disease was
defined as skin bleeding (ecchymoses not petechiae) on
admission to hospital,19 rash noted by referring general
practitioner,8 septicaemia with hypotension (systolic blood pres-
sure ≤ 70 mm Hg in those aged ≤ 12 years; ≤ 100 mm Hg in
those aged > 12 years) or ecchymoses, or both, but no signs of
meningitis,22 diagnosis suspected by referring doctor,26 and
haemorrhagic rash on hospital admission.15 Three of these five
studies presented data on patients seen in primary care. The 2
for heterogeneity was 7.97 (P = 0.02), I2 = 75% (95% uncertainty
interval 17% to 92%). In two studies parenteral treatment was
associated with a beneficial effect on mortality among severe
cases,8 26 whereas in one19 it was associated with an adverse effect
(table 3). None of these effects was significant.
Explaining the heterogeneity
The estimated variance between studies in the log risk ratio from
the meta-regression with the proportion of cases treated as a
covariate was 0.000 v 0.2263 from the “null” model. Thus, the
proportion of cases treated explains 100% of the variance
between studies.We found a log linear relation such that a higher
proportion of patients given parenteral antibiotics before admis-
sion was associated with reduced mortality after such treatment
and vice versa (P = 0.04, fig 4). The proportion of cases classified
as severe did not explain the heterogeneity between studies.
Norgard 2002
Morant 1999
Barquet 2000
Strang 1992
Garcia 1986
0.25 (0.02 to 4.05)
0.42 (0.05 to 3.33)
0.08 (0.02 to 0.32)
0.31 (0.02 to 4.74)
0.23 (0.01 to 3.85)
Risk ratio (95% CI)Risk ratio (95% CI)
0.01 0.05 0.1 0.25 0.5 1 42 53
Favours
treatment
Favours
control
Fig 2 Estimated risk ratio for death in studies of oral antibiotic treatment before
admission (square size is proportionate to study size)
Gunnell 1994
Martin 1999
Jefferies 1999
Strang 1992
Cartwright 1992
Norgard 2002
Palmer 1992
1.06 (0.19 to 5.72)
0.35 (0.16 to 0.80)
0.85 (0.08 to 8.93)
0.16 (0.01 to 2.63)
0.60 (0.23 to 1.54)
1.81 (0.88 to 3.70)
0.97 (0.13 to 7.30)
Risk ratio (95% CI)Risk ratio (95% CI)
0.01 0.25 0.5 1 155 2510
Favours
treatment
Favours
control
Fig 3 Estimated risk ratio for death in those studies of parenteral antibiotic
treatment before admission in which all reported patients were seen in primary
care (square size is proportionate to study size)
Table 2 Cases of meningococcal disease and outcome stratified by parenteral treatment before admission, not excluding patients treated with oral antibiotics
before admission
Study Primary care*
No of
deaths/No
treated
No of deaths/No not
treated Total (% treated) Case fatality (%) Risk ratio for death† (95% CI) Antibiotic treatment
Barquet18 No 1/41 40/602 643 (6) 6.4 0.37 (0.05 to 2.60) Parenteral
Cartwright8 Yes 5/93 22/246 339 (27) 8.0 0.60 (0.23 to 1.54) Parenteral
Gunnell25 Yes 3/27 2/19 46 (59) 10.9 1.06 (0.19 to 5.72) Benzyl penicillin
Halstensen22 No 2/11 16/200 211 (5) 8.5 2.27 (0.60 to 8.67) Parenteral
Jefferies16 Yes 1/24 2/41 65 (37) 4.6 0.85 (0.08 to 8.93) Parenteral
Jolly20 No 2/72 16/186 258 (28) 7.0 0.32 (0.08 to 1.37) Benzyl penicillin
Martin14 Yes 7/442 29/650 1092 (40) 3.3 0.35 (0.16 to 0.80) Parenteral
Norgard19 Yes 9/77 26/402 479 (16) 7.3 1.81 (0.88 to 3.70) Parenteral
Palmer23 Yes 1/11 6/64 75 (15) 9.3 0.97 (0.13 to 7.30) Penicillin
Strang26 Yes 0/13 6/28 41 (32) 14.6 0.16 (0.01 to 2.63) Penicillin
Wood21 No 1/7 2/33 40 (18) 7.5 2.36 (0.25 to 22.54) Benzyl penicillin
Woodward15 No 0/13 3/55 68 (19) 4.4 0.57 (0.03 to 10.43) Parenteral
Total — 32/831 170/2526 3357 (25) 6.0 — —
*Study restricted to patients seen in primary care.
†In studies in which there were no deaths in those treated with antibiotics, we added 0.5 to each of the four cells in the 2×2 table before analysis.
Table 3 Cases of meningococcal disease and outcome stratified by parenteral treatment before admission, not excluding patients treated with oral antibiotics
before admission, in those cases classified as severe
Study Primary care*
No of deaths/No
treated No of deaths/No not treated Total (% treated) Case fatality (%) Risk ratio for death† (95% CI)
Cartwright8 Yes 4/75 12/102 177 (42) 9.0 0.45 (0.15 to 1.35)
Halstensen22 No 2/4 12/35 39 (10) 35.9 1.46 (0.49 to 4.30)
Norgard19 Yes 7/16 7/37 53 (30) 26.4 2.31 (0.97 to 5.51)
Strang26 Yes 0/13 4/18 31 (42) 12.9 0.15 (0.01 to 2.58)
Woodward15 No 0/12 3/35 47 (26) 6.4 0.40 (0.02 to 7.15)
Total — 13/120 38/227 347 (35) 14.7 —
*Study restricted to patients seen in primary care.
†In studies in which there were no deaths in those treated with antibiotics, we added 0.5 to each of the four cells in the 2×2 table before analysis.
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Discussion
We must be cautious in drawing conclusions from this systematic
review of the effects of antibiotic treatment before admission on
survival from meningococcal disease. Though all of the studies
included were observational, they can provide useful informa-
tion in instances where randomised controlled trials are unethi-
cal or impracticable. Such studies, however, are prone to bias and
confounding. In studies in which associations between treatment
and outcome are investigated, such as those included in our
review, prognostic factors may systematically differ between
compared treatment groups as a doctor’s perception of severity
is likely to determine the choice of treatment. This leads to con-
founding by severity.29
Studies in our review with data on oral antibiotics given
before admission showed consistently improved survival among
patients with meningococcal disease who received such
treatment compared with those who did not. This is hardly sur-
prising as doctors are likely to prescribe oral antibiotics only
when they do not consider the diagnosis to be meningococcal
disease. The latter is more probable in case of milder or slower
progressing disease. Therefore we consider that the observed
beneficial effect of oral antibiotics on survival is strongly
confounded by severity, and we cannot conclude that the positive
effect is genuine.
The effect of parenteral antibiotics was inconsistent in the
papers included in our review. This inconsistency precluded esti-
mation of a combined effect through meta-analysis. After we
adjusted for the proportion of cases treated, the heterogeneity
was removed. A higher proportion of patients given parenteral
antibiotics before admission was associated with reduced
mortality after such treatment and vice versa. This observation
could be explained either through confounding by severity or by
effect modification.
Confounding
Confounding could account for an adverse effect if studies in
which a lower proportion is treated are biased towards treating
those with a higher a priori chance of dying. For example, in
Denmark, at the time of the study of Norgard et al,19 antibiotics
before admission were recommended only in those cases of sus-
pected meningococcal disease when petechiae or other signs of
meningococcal sepsis were present or if the patient showed
other signs of severe meningitis and the transport time to the
nearest hospital was more than half an hour.
Effect modification
Effect modification, where the strength and direction of the asso-
ciation between parenteral antibiotics before admission and
mortality depend on the proportion of cases treated, could also
explain the observations in our review. This would imply a harm-
ful effect of treatment when a low proportion of cases is treated,
presumably in those with more severe disease.7 The main
concern with parenteral antibiotic treatment before admission is
that treatment facilities in primary care may be inadequate to
deal with haemodynamic instability that might result from mas-
sive release of meningococcal endotoxins during initial phases of
the therapy.7 However, this argument is not supported by experi-
mental evidence. Prins et al found that free endotoxin and
cytokine concentrations were significantly lower after exposure
to antibiotics in vitro compared with in untreated samples.30 Also,
in vivo studies have consistently shown rapid decreasing concen-
trations of lipopolysaccharides (the main endotoxin) after bacte-
ricidal antibiotic treatment in meningococcal disease.31 A
case-control study published since we completed this review
found an adverse effect on outcome of antibiotics before admis-
sion but no evidence of clinical deterioration in the interval
between administration of penicillin and admission to hospital.32
Fear of anaphylactic reactions to benzyl penicillin could pre-
vent general practitioners from treating patients when meningo-
coccal disease is suspected, but genuine anaphylaxis is rare; it is
estimated to occur in about 1 in 7000-25 000 cases.33 Other con-
cerns that have been raised argue that antibiotic treatment
before admission may lower the proportion of patients who can
subsequently be diagnosed by microbiological tests and delay the
start of appropriate treatment in hospital.34 35 Clearly, this
argument against giving antibiotics before admission is valid
only if any adverse effect on outcome is greater than any positive
effect of treatment before admission. Also, there are diagnostic
alternatives available, such as polymerase chain reaction in blood
or cerebrospinal fluid, or isolation of meningococci from the
posterior pharyngeal wall, which are much less affected by previ-
ous benzyl penicillin treatment.36
Confounding by severity is the most likely explanation both
for the beneficial effect of oral antibiotics and the harmful effect
observed in some studies of parenteral antibiotics. It is unlikely
that studies of sufficient quality to give evidence of the effective-
ness of antibiotic treatment before admission on survival in
meningococcal disease will become available. Studies with
detailed data on severity of disease, disease evolution, and char-
acteristics of subsequent hospital treatment could allow
improved adjustment for confounding. As severity of disease and
disease evolution are difficult to measure accurately, especially in
retrospective studies, adequate adjustment for these factors is not
likely to be achievable. Randomised controlled trials investigat-
ing the effect of antibiotic treatment before admission on
outcome of meningococcal disease would be needed to examine
this question. Such studies may never be done in view of the
anticipated logistical and ethical difficulties. We cannot conclude
from this review whether or not antibiotics given before
admission have an effect on case fatality. The data are consistent
with benefit when a substantial proportion of cases are treated.
We thank the librarians at the Public Health Laboratory Service, Colindale,
for help with the search strategy, and Natasha Crowcroft, Keith Cartwright,
and Deirdre Lewis for useful suggestions during preparation of the paper.
Contributions: JMS initiated the working group, SJMH, BP, SS, IC, IE, SH,
and MS were members of the working group sharing discussions on meth-
ods, findings, and interpretations. SJMH and JMS reviewed all included
papers and are guarantors. SJMH extracted the data. AC did the statistical
analyses. All authors contributed to writing the paper.
Proportion of cases treated
Ri
sk
 ra
tio
0.1 0.2 0.3 0.4 0.5 0.6
0
0.5
1.0
1.5
2.0
2.5
Fig 4 Relation between estimated risk ratio and proportion of treated cases in
those studies of parenteral antibiotic treatment before admission in which all
reported patients were seen in primary care (circle size is proportionate to study
size; the solid line indicates the best fit regression model; the broken line
indicates the 95% confidence interval for this)
Research
page 4 of 5 BMJ Online First bmj.com
 on 26 October 2006 bmj.comDownloaded from 
Funding: SJMH and IC received funding from the European Programme
for Intervention Epidemiology Training (EPIET), which is funded by the
European Commission under the agreement numbers Soc 98 200634.05
F01 and SI2 74030 (99CVVF4-003.0). Two meetings of the working group
were supported by Wyeth Lederle.
Competing interests: None declared.
Ethical approval: Not required.
1 European Union Invasive Bacterial Infection Surveillance Network. Invasive Neisseria
meningitidis in Europe, 2002. www.euibis.org/documents/2002_meningo.pdf (accessed
20 Apr 2006).
2 Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against menin-
gococcal disease. Lancet 2002;359:1499-508.
3 Cartwright K. Introduction and historical aspects. In: Cartwright K, ed. Meningococcal
disease. Chichester: John Wiley, 1995:1-19.
4 Flexner S. The result of serum treatment in thirteen hundred cases of epidemic menin-
gitis. J Exp Med 1913;17:553-76.
5 Booy R, Habibi P, Nadel S, de Munter C, Britto J, Morrison A, et al. Reduction in case
fatality rate from meningococcal disease associated with improved healthcare delivery.
Arch Dis Child 2001;85:386-90.
6 Nadel S, Britto J, Booy R, Maconochie I, Habibi P, Levin M. Avoidable deficiencies in
the delivery of health care to children with meningococcal disease. J Accid Emerg Med
1998;15:298-303.
7 Sorensen HT, Nielsen GL, Schonheyder HC, Steffensen FH, Hansen I, Sabroe S, et al.
Outcome of pre-hospital antibiotic treatment of meningococcal disease. J Clin
Epidemiol 1998;51:717-21.
8 Cartwright K, Reilly S, White D, Stuart J. Early treatment with parenteral penicillin in
meningococcal disease. BMJ 1992;305:143-7.
9 Public Health Laboratory Service. Pre-admission benzyl penicillin for suspected
meningococcal disease: other antibiotics not needed in the GP bag. www.hpa.org.uk/
cdr/archives/2001/cdr0701.pdf (accessed 20 Apr 2006).
10 Purcell B, Samuelsson S, Hahné SJM, Ehrhard I, Heuberger S, Camaroni I, et al. Effec-
tiveness of antibiotics in preventing meningococcal disease after a case: systematic
review. BMJ 2006;328:1339-42.
11 Bradburn MJ, Deeks JJ, Altman DG. sbe24: metan—an alternative meta-analysis
command. Stata Tech Bull 1998;44:4-15.
12 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
meta-analyses. BMJ 2003;327:557-60.
13 Sharp S. Meta-analysis regression. Stata Tech Bull 1998;42:16-22.
14 Martin D, Kieft C, Miller J. The epidemiology of meningococcal disease in New Zealand in
1998. A report to the Ministry of Health. [Unpublished Report 1999].
15 Woodward CM, Jessop EG, Wale MC. Early management of meningococcal disease.
Commun Dis Rep CDR Rev 1995;5:R135-7.
16 Jefferies C, Lennon D, Stewart J, Martin D. Meningococcal disease in Auckland, July
1992-June 1994. N Z Med J 1999;112:115-7.
17 Morant Gimeno A, Diez Domingo J, Gimeno Cardona C, Pereiro Berenguer I, Brines
Solanes J, Sauri Marti V. Analisis del tratamiento antibiotico previo sobre el impacto de
la enfermedad meningococica en ninos de la Comunidad Valenciana [An analysis of
prior antiobiotic treatment of the impact of meningococcal disease in children of the
Valencian Community]. An Esp Pediatr 1999;50:17-20.
18 Barquet N, Domingo P, Cayla JA. Oral antibiotics and outcome in meningococcemia.
Arch Intern Med 2000;160:2221-3.
19 Norgard B, Sorensen HT, Jensen ES, Faber T, Schonheyder HC, Nielsen GL.
Pre-hospital parenteral antibiotic treatment of meningococcal disease and case fatality:
a Danish population-based cohort study. J Infect 2002;45:144-51.
20 Jolly K, Stewart G. Epidemiology and diagnosis of meningitis: results of a five-year pro-
spective, population-based study. Commun Dis Public Health 2001;4:124-9.
21 Wood AL, O’Brien SJ. How long is too long? Determining the early management of
meningococcal disease in Birmingham. Public Health 1996;110:237-9.
22 Halstensen A, Pedersen SH, Haneberg B, Bjorvatn B, Solberg CO. Case fatality of
meningococcal disease in western Norway. Scand J Infect Dis 1987;19:35-42.
23 Palmer SR, Corson J, Hall R, Payne S, Ludlow J, Deere B, et al. Meningococcal disease
in Wales: clinical features, outcome and public health management. J Infect
1992;25:321-8.
24 Garcia Munoz MT, Espinosa Perez J, Franganillo Fernandez A, Cerezo Pancorbo JM,
Sanchez Badia JL. Tratamiento antibiotico previo en la infeccion meningococica [Pre-
vious antibiotic treatment in meningococcal infection]. An Esp Pediatr 1986;24:213-6.
25 Gunnell DJ, Pearson N, Ley B, Hill A. Epidemiology of meningococcal disease and a
community outbreak in Somerset. Commun Dis Rep CDR Rev 1994;4:R101-4.
26 Strang JR, Pugh EJ. Meningococcal infections: reducing the case fatality rate by giving
penicillin before admission to hospital. BMJ 1992;305:141-3.
27 Barquet N, Domingo P, Cayla JA, Gonzalez J, Rodrigo C, Fernandez-Viladrich P, et al.
Prognostic factors in meningococcal disease. Development of a bedside predictive
model and scoring system. Barcelona Meningococcal Disease Surveillance Group.
JAMA 1997;278:491-6.
28 Domingo P, Barquet N, Cayla JA. Sore throat, antibiotics, and progression to meningo-
coccal disease. Lancet 1995;345:460.
29 Vandenbroucke JP. When are observational studies as credible as randomised trials?
Lancet 2004;363:1728-31.
30 Prins JM, Speelman P, Kuijper EJ, Dankert J, van Deventer SJH. No increase in
endotoxin release during antibiotic killing of meningococci. J Antimicrob Chemother
1997;39:13-8.
31 Brandtzaeg P. Pathogenesis of meningococcal infections. In: Cartwright K, ed.Meningo-
coccal disease. Chichester: John Wiley, 1995:79-80.
32 Harnden A, Ninis N, Thompson M, Perera R, Levin M, Mant D, et al. Parenteral penicil-
lin for children with meningococcal disease before hospital admission: case-control
study. BMJ 2006;332:1295-7.
33 Idsoe O, Guthe T, Willcox RR, de Weck AL. Nature and extent of penicillin
side-reactions with particular reference to fatalities from anaphylactic shock. Bull World
Health Organ 1968;38:159-88.
34 Bohr V, Rasmussen N, Hansen B, Kjersem H, Jessen O, Johnsen N, et al. 875 cases of
bacterial meningitis: diagnostic procedures and the impact of preadmission antibiotic
therapy. Part III of a three-part series. J Infect 1983;7:193-202.
35 Sorensen HT, Moller-Petersen J, Krarup HB, Pedersen H, Hansen H, Hamburger H.
Diagnostic problems with meningococcal disease in general practice. J Clin Epidemiol
1992;45:1289-93.
36 Cartwright K, Kroll S. Optimising the investigation of meningococcal disease. BMJ
1997;315:757-8.
(Accepted 10 May 2006)
bmj.com 2006;332:1299
National Institute for Public Health and the Environment (RIVM), Bilthoven,
Netherlands
Susan J M Hahné medical epidemiologist
Statistics, Modelling and Bioinformatics Department, Centre for Infections, Health
Protection Agency, London
Andr Charlett
interim directorSussex Health Protection Unit, Health Protection Agency, Lewes,
East Sussex
Bernadette Purcell consultant in communicable disease control
Statens Serum Institut (SSI), Copenhagen, Denmark
Susanne Samuelsson medical epidemiologist
Department of Epidemiology, Smittskyddsinstitutet (SMI), Stockholm, Sweden
Ivonne Camaroni medical doctor
Public Health Laboratory of Saxony, Dresden, Germany
Ingrid Ehrhard medical microbiologist
Austria National Reference Centre for Meningococci, Austrian Agency for Food
and Health Safety, Graz, Austria
Sigrid Heuberger head
WHO, Communicable Disease Surveillance and Response (CSR), Geneva,
Switzerland
Maria Santamaria medical officer
Health Protection Agency South West, Stonehouse, Gloucestershire
James M Stuart regional director
Correspondence to: S Hahné susan.hahne@rivm.nl
What is already known on this topic
Delay in starting antibiotic treatment of meningococcal
disease in hospital has an adverse effect on outcome
National guidelines in several European countries advise
doctors in primary care to give parenteral antibiotics to
patients with suspected meningococcal disease before
transfer to hospital, though evidence of benefit is conflicting
What this study adds
Robust evidence of benefit (or harm) may never be
obtained
Lower mortality after parenteral antibiotics before
admission is associated with a higher proportion treated
and vice versa
Research
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